Exelixis Inc (EXEL)

[axelvento]

Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
June 20, 2025


– A regulatory decision by the European Medicines Agency is anticipated in 2025 –

– In March 2025, the U.S. Food and Drug Administration approved CABOMETYX in this setting –

https://www.biospace.com/press-releases/exelixis-partner-ipsen-receives-positive-chmp-opinion-for-cabometyx-cabozantinib-for-patients-with-previously-treated-advanced-neuroendocrine-tumors